Cosmos Health Valuation

Is V67A undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of V67A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate V67A's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate V67A's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for V67A?

Key metric: As V67A is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for V67A. This is calculated by dividing V67A's market cap by their current revenue.
What is V67A's PS Ratio?
PS Ratio	0.3x
Sales	US$56.04m
Market Cap	US$15.63m

V67A key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.4x
Enterprise Value/EBITDA	-1.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does V67A's PS Ratio compare to its peers?

The above table shows the PS ratio for V67A vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.2x
HAEK HAEMATO	0.3x	n/a	€68.0m
TLIK Arzneiwerk VIDA	0.08x	n/a	€4.5m
ILM1 Medios	0.2x	6.1%	€334.7m
JTH Gesundheitswelt Chiemgau	0.3x	n/a	€24.4m
V67A Cosmos Health	0.3x	n/a	€15.6m

Price-To-Sales vs Peers: V67A is expensive based on its Price-To-Sales Ratio (0.3x) compared to the peer average (0.2x).

Price to Sales Ratio vs Industry

How does V67A's PS Ratio compare vs other companies in the DE Healthcare Industry?

1 Company	Price / Sales	Estimated Growth	Market Cap
TLIK Arzneiwerk VIDA	0.08x	n/a	US$4.67m

No more companies available in this PS range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: V67A is good value based on its Price-To-Sales Ratio (0.3x) compared to the European Healthcare industry average (0.6x).

Price to Sales Ratio vs Fair Ratio

What is V67A's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

V67A PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.3x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate V67A's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

LNA Santé

€244.4m

Engages in the management and operation of health establishments.

2N3

€23.25

-6.1%

16.0%

Shandong Weigao Group Medical Polymer

HK$20.1b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

-1.0%

-38.8%

OrbusNeich Medical Group Holdings

HK$3.4b

An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.

Q8T

HK$0.51

12.2%

-43.3%